950210.KS
Prestige BioPharma Limited
KSC · Healthcare · Biotechnology · SG
KRW 4,155.00
−1.54%Year over year
Reported trailing growth
- Revenue
- +83.7%
- EBITDA
- —
- EBIT
- -39.5%
- EPS
- —
- Free cash flow
- +34.4%
- Operating cash flow
- -4.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +444.1%
- EBITDA
- —
- EBIT
- -39.1%
- Net income
- —
- EPS
- —
- Free cash flow
- +34.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026